Congenital Syphilis: Policy Pathways to Reverse the Rise
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- This finding is notably relevant for individuals with pre-existing cardiovascular disease, including those with a history of heart attack, stroke, or peripheral artery disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults wiht obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated meaningful weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk.However, it’s crucial to note that the trial did *not* meet its primary endpoint of reducing MACE, despite the significant weight loss observed in the semaglutide group (an average of approximately 15% of body weight).
| Outcome | semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| Major Adverse Cardiovascular event (MACE) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.7 | 2.9 | 1.29 |
| Non-Fatal Stroke | 2.6 | 1.7 | 1.55 |
| Non-Fatal Heart Attack | 1.9 | 1.3 | 1.46 |
Who is Affected? Understanding the Patient Population
This finding is notably relevant for individuals with pre-existing cardiovascular disease, including those with a history of heart attack, stroke, or peripheral artery disease. The SELECT trial specifically enrolled participants with established cardiovascular disease, meaning the increased risk wasn’t observed in a generally healthy obese population. It’s vital to emphasize that this doesn’t necessarily mean semaglutide is harmful for *all* obese individuals, but it does highlight the need for careful risk-benefit assessment in those with cardiovascular vulnerabilities.
The trial included participants with a Body Mass Index (BMI) of 27 or higher, and at least one cardiovascular event within the past 24 months. This specific inclusion criteria are vital to understanding the scope of these findings.
Why Does This Matter? The Implications for Weight Loss Medications
The widespread use of semaglutide and other GLP-1 receptor agonists for weight loss has been rapidly increasing. These medications have been lauded for their efficacy in promoting weight reduction, but the SELECT trial introduces a critical caveat. The results underscore the importance of considering the potential cardiovascular risks, especially in vulnerable populations. This finding may lead to more cautious prescribing practices and a reevaluation of the overall risk-benefit profile of these drugs.